Zaiying Hu1, Xiaohong Wang2, Jun Qi1, QingCong Kong2, Minjing Zhao1, Jieruo Gu3. 1. Department of rheumatology, the third affiliated hospital, Sun Yat-Sen university, 600, Tianhe Road, 510630 Guangzhou, China. 2. Department of radiology, the third affiliated hospital, Sun Yat-Sen university, 600, Tianhe Road, 510630 Guangzhou, China. 3. Department of rheumatology, the third affiliated hospital, Sun Yat-Sen university, 600, Tianhe Road, 510630 Guangzhou, China. Electronic address: gujieruo@163.com.
Abstract
OBJECTIVES: To summarize the characteristics of backfill in patients with axial spondyloarthritis (SpA) and patients with non-specific back pain (NSBP) and healthy controls, and to assess the value of backfill in diagnosing axial SpA. METHODS: Three readers blinded recorded backfill seen on T1SE MRI scans from 647 subjects: 297 patients with ankylosing spondylitis (AS), 126 patients with non-radiographic axial SpA (nr-axSpA), 147 patients with NSBP, and 77 healthy controls. The SPARCC SIJ Structural Score (SSS) method was used to assess backfill. The changes of backfill were evaluated by the follow-up MRI scans from 157 patients. We summarized the characteristics of backfill and calculated its sensitivity and specificity for diagnosing axial SpA. RESULTS: Backfill was recorded in 78.8% AS patients, 11.1% nr-axSpA patients, 1.8% patients with NSBP, and no healthy control. Backfill affected more frequently at ilium bone, lower half of sacroiliac joints in axial SpA (both P<0.05). The SSS score of backfill was much higher in axial SpA than in patients with NSBP (both P<0.01) and it did not correlate with demographics and BASDAI, BASFI, and CRP (all P>0.05). The score of backfill only positively correlated with symptom duration in AS (r=0.251, P<0.01) and in nr-axSpA (r=0.743, P<0.01) patients. Only 8.9% patients had the change of backfill in an average follow-up time of 1.09 years. Backfill had high specificity (0.98) and moderate sensitivity (0.59) for diagnosing axial SpA. CONCLUSIONS: We summarized the characteristics of backfill and found that backfill is a specific sign of axial SpA seen on T1SE MRI.
OBJECTIVES: To summarize the characteristics of backfill in patients with axial spondyloarthritis (SpA) and patients with non-specific back pain (NSBP) and healthy controls, and to assess the value of backfill in diagnosing axial SpA. METHODS: Three readers blinded recorded backfill seen on T1SE MRI scans from 647 subjects: 297 patients with ankylosing spondylitis (AS), 126 patients with non-radiographic axial SpA (nr-axSpA), 147 patients with NSBP, and 77 healthy controls. The SPARCC SIJ Structural Score (SSS) method was used to assess backfill. The changes of backfill were evaluated by the follow-up MRI scans from 157 patients. We summarized the characteristics of backfill and calculated its sensitivity and specificity for diagnosing axial SpA. RESULTS: Backfill was recorded in 78.8% AS patients, 11.1% nr-axSpA patients, 1.8% patients with NSBP, and no healthy control. Backfill affected more frequently at ilium bone, lower half of sacroiliac joints in axial SpA (both P<0.05). The SSS score of backfill was much higher in axial SpA than in patients with NSBP (both P<0.01) and it did not correlate with demographics and BASDAI, BASFI, and CRP (all P>0.05). The score of backfill only positively correlated with symptom duration in AS (r=0.251, P<0.01) and in nr-axSpA (r=0.743, P<0.01) patients. Only 8.9% patients had the change of backfill in an average follow-up time of 1.09 years. Backfill had high specificity (0.98) and moderate sensitivity (0.59) for diagnosing axial SpA. CONCLUSIONS: We summarized the characteristics of backfill and found that backfill is a specific sign of axial SpA seen on T1SE MRI.
Authors: Alexis Jones; Timothy J P Bray; Peter Mandl; Margaret A Hall-Craggs; Helena Marzo-Ortega; Pedro M Machado Journal: Rheumatology (Oxford) Date: 2019-11-01 Impact factor: 7.580
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372